- Home
- GOODO vs CGEN Comparison
GOODO vs CGEN Comparison
Compare GOODO & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOODO
- CGEN
- Stock Information
- Founded
- GOODO N/A
- CGEN 1993
- Country
- GOODO United States
- CGEN Israel
- Employees
- GOODO 69
- CGEN 68
- Industry
- GOODO Real Estate
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GOODO Real Estate
- CGEN Health Care
- Exchange
- GOODO Nasdaq
- CGEN Nasdaq
- Market Cap
- GOODO N/A
- CGEN 126.2M
- IPO Year
- GOODO N/A
- CGEN 2000
- Fundamental
- Price
- GOODO $22.02
- CGEN $1.41
- Analyst Decision
- GOODO
- CGEN Strong Buy
- Analyst Count
- GOODO 0
- CGEN 2
- Target Price
- GOODO N/A
- CGEN $4.00
- AVG Volume (30 Days)
- GOODO N/A
- CGEN 277.1K
- Earning Date
- GOODO N/A
- CGEN 11-12-2024
- Dividend Yield
- GOODO N/A
- CGEN N/A
- EPS Growth
- GOODO N/A
- CGEN N/A
- EPS
- GOODO N/A
- CGEN 0.02
- Revenue
- GOODO N/A
- CGEN $59,852,000.00
- Revenue This Year
- GOODO N/A
- CGEN $18.69
- Revenue Next Year
- GOODO N/A
- CGEN N/A
- P/E Ratio
- GOODO N/A
- CGEN $78.70
- Revenue Growth
- GOODO N/A
- CGEN 698.03
- 52 Week Low
- GOODO N/A
- CGEN $0.61
- 52 Week High
- GOODO N/A
- CGEN $3.03
- Technical
- Relative Strength Index (RSI)
- GOODO 53.80
- CGEN 31.04
- Support Level
- GOODO $21.82
- CGEN $1.54
- Resistance Level
- GOODO $22.10
- CGEN $1.85
- Average True Range (ATR)
- GOODO 0.24
- CGEN 0.10
- MACD
- GOODO -0.04
- CGEN -0.02
- Stochastic Oscillator
- GOODO 34.00
- CGEN 10.20
About GOODO Gladstone Commercial Corporation 6.00% Series G Cumulative Redeemable Preferred Stock par value $0.001 per share
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.